Tag: CLARINET clinical trial
Breaking News: US FDA Approves Lanreotide for Gastroenteropancreatic Neuroendocrine Tumors
December 16, 2014
December 16, 2014: The US Food and Drug Administration (FDA) today approved “lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic…
READ MORE
10 Highlights of the Year 2013 for the Carcinoid and Neuroendocrine Tumor Community
December 18, 2013
As the Carcinoid Cancer Foundation looks back on the year 2013, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…
READ MORE
